Keyphrases
Hospitalization
100%
Inflammatory Bowel Disease
100%
Venous Thromboembolism
100%
Quality-adjusted Life Years
100%
Cost-effectiveness
100%
Venous Thromboembolism Prophylaxis
100%
Rivaroxaban
50%
Number-needed-to-treat
50%
Venous Thromboembolism Risk
33%
Incremental Cost-effectiveness Ratio
33%
Risk Profile
16%
Hospitalized Patients
16%
Clinical High Risk
16%
Patient Preference
16%
Willingness to Pay
16%
Probabilistic Sensitivity Analysis
16%
One-way Sensitivity Analysis
16%
Risk Cost
16%
Societal Perspective
16%
Decision Tree
16%
Incremental Cost
16%
Probabilistic Analysis
16%
Model Uncertainty
16%
Medicine and Dentistry
Patient with Inflammatory Bowel Disease
100%
Venous Thromboembolism
100%
Cost-Effectiveness Analysis
100%
Quality Adjusted Life Year
46%
Health Care Cost
38%
Numbers Needed to Treat
23%
Rivaroxaban
23%
Patient Preference
7%
Inflammatory Bowel Disease
7%
Nursing and Health Professions
Venous Thromboembolism
100%
Cost Effectiveness Analysis
100%
Patient with Inflammatory Bowel Disease
100%
Quality Adjusted Life Year
46%
Numbers Needed to Treat
23%
Rivaroxaban
23%
Incremental Cost-Effectiveness Ratio
15%
Inflammatory Bowel Disease
7%
Patient Preference
7%
Decision Trees
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Venous Thromboembolism
100%
Rivaroxaban
23%
Number Needed to Treat
23%